Shandong's gold performance is expected to improve. The reas...

Shandong's gold performance is expected to improve. The reasons include the possibility that the price of gold will rise again, the acquisition of Yintai's production capacity will increase, and other asset injections. Junshi Biotech's treprilizumab sales are expected to exceed 3 billion dollars. The prospects for overseas markets are broad, the company's valuation is low, and cash flow can be expected to improve.